Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

NIH 2 INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 18 Myeloid 8 Gastrointestinal 5 Tumor-Agnostic 1 Sarcoma 1 Lymphoid 1 Classical hematology 1 CNS 1

Conditions

Interventions

Temozolomide 400 Radiotherapy 239 Bevacizumab 185 Magnetic Resonance Spectroscopy 168 Radiosurgery 142 Cyclophosphamide 95 Irinotecan 79 Carboplatin 79 Etoposide 78 Radiation 76 pembrolizumab 70 Nivolumab 59 Surgical Procedures, Operative 57 Filgrastim 56 Specimen Handling 53 Cisplatin 50 Blood Specimen Collection 46 Topotecan 45 Vincristine 43 Melphalan 38 Radiotherapy, Intensity-Modulated 36 Pemetrexed 36 Lomustine 36 Ipilimumab 36 Everolimus 35 Magnetic Resonance Imaging 34 Erlotinib Hydrochloride 34 Drug Therapy 34 Surveys and Questionnaires 33 sargramostim 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × ivosidenib × CNS × Clear all

NCT04056910 2025-02-27

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

University of Pittsburgh

Phase 2 Completed

15 enrolled 14 charts

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡